← Back to All US Stocks

FTLF Stock Analysis 2026 - FITLIFE BRANDS, INC. AI Rating

FTLF Nasdaq Medicinal Chemicals & Botanical Products NV CIK: 0001374328
Recently Updated • Analysis: Mar 25, 2026 • SEC Data: 2025-09-30
BUY
72% Conf
Pending
Analysis scheduled

📊 FTLF Key Takeaways

Revenue: $55.5M
Net Margin: 8.4%
Free Cash Flow: $7.2M
Current Ratio: 1.13x
Debt/Equity: 1.11x
EPS: $0.47
AI Rating: BUY with 72% confidence

Is FTLF a Good Investment? Thesis Analysis

Claude

FitLife Brands demonstrates strong fundamental growth with 22.3% YoY revenue expansion and exceptional 69.6% net income growth, supported by healthy 40.5% gross margins and 14.0% operating margins. The company generates solid free cash flow of $7.2M with a 12.9% FCF margin, though elevated leverage (1.11x Debt/Equity) and tight liquidity (1.13x current ratio) require monitoring as the company scales.

Why Buy FTLF? Key Strengths

Claude
  • + Strong revenue growth of 22.3% YoY with net income growth of 69.6% indicating operational leverage
  • + Healthy profitability metrics with 40.5% gross margin and 14.0% operating margin in medicinal/botanical sector
  • + Solid free cash flow generation of $7.2M with 12.9% FCF margin demonstrating cash conversion ability
  • + Strong interest coverage ratio of 18.8x indicates sufficient earnings to service debt obligations

FTLF Investment Risks to Consider

Claude
  • ! Elevated leverage with 1.11x Debt/Equity ratio and $46.5M long-term debt against $41.9M equity
  • ! Tight liquidity position with 1.13x current ratio and low cash balance of $3.5M relative to $68.1M liabilities
  • ! Quick ratio of 0.46x suggests potential working capital stress if inventory cannot be quickly liquidated
  • ! No recent insider buying activity (0 Form 4 filings in 90 days) may indicate limited management confidence

Key Metrics to Watch

Claude
  • * Operating cash flow sustainability and ability to maintain 12.9% FCF margin as revenue scales
  • * Debt reduction trajectory and long-term Debt/Equity ratio movement toward healthier levels
  • * Working capital management and current ratio improvement to mitigate liquidity risk
  • * Gross margin stability as company expands in competitive medicinal/botanical products sector

FTLF Financial Metrics

Revenue
$55.5M
Net Income
$4.7M
EPS (Diluted)
$0.47
Free Cash Flow
$7.2M
Total Assets
$110.0M
Cash Position
$3.5M

💡 AI Analyst Insight

FITLIFE BRANDS, INC. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

FTLF Profitability Ratios

Gross Margin 40.5%
Operating Margin 14.0%
Net Margin 8.4%
ROE 11.2%
ROA 4.3%
FCF Margin 12.9%

FTLF vs Default Sector

How FITLIFE BRANDS, INC. compares to Default sector averages

Net Margin
FTLF 8.4%
vs
Sector Avg 12.0%
FTLF Sector
ROE
FTLF 11.2%
vs
Sector Avg 15.0%
FTLF Sector
Current Ratio
FTLF 1.1x
vs
Sector Avg 1.8x
FTLF Sector
Debt/Equity
FTLF 1.1x
vs
Sector Avg 0.7x
FTLF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is FTLF Overvalued or Undervalued?

Based on fundamental analysis, FITLIFE BRANDS, INC. has mixed fundamental signals relative to the Default sector in 2026.

Return on Equity
11.2%
Sector avg: 15%
Net Profit Margin
8.4%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
1.11x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

FTLF Balance Sheet & Liquidity

Current Ratio
1.13x
Quick Ratio
0.46x
Debt/Equity
1.11x
Debt/Assets
61.9%
Interest Coverage
18.83x
Long-term Debt
$46.5M

FTLF 5-Year Financial Trend & Growth Analysis

FTLF 5-year financial data: Year 2021: Revenue $27.9M, Net Income $8.8M, EPS $1.94. Year 2022: Revenue $28.8M, Net Income $5.4M, EPS $1.13. Year 2023: Revenue $52.7M, Net Income $4.4M, EPS $0.89. Year 2024: Revenue $64.5M, Net Income $5.3M, EPS $0.54.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: FITLIFE BRANDS, INC.'s revenue has grown significantly by 131% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.54 reflects profitable operations.

FTLF Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
12.9%
Free cash flow / Revenue

FTLF Quarterly Performance

Quarterly financial performance data for FITLIFE BRANDS, INC. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $16.0M $921.0K $0.09
Q2 2025 $16.1M $1.7M $0.18
Q1 2025 $15.9M $2.0M $0.20
Q3 2024 $13.9M $1.7M $0.35
Q2 2024 $14.8M $2.0M $0.40
Q1 2024 $10.7M $156.0K $0.03
Q3 2023 $8.3M $1.2M $0.24
Q2 2023 $7.8M $1.4M $0.29

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

FTLF Capital Allocation

Operating Cash Flow
$7.2M
Cash generated from operations
Capital Expenditures
$37.0K
Investment in assets
Dividends
None
No dividend program

FTLF SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for FITLIFE BRANDS, INC. (CIK: 0001374328)

📋 Recent SEC Filings

Date Form Document Action
Dec 10, 2025 8-K ftlf20251210_8k.htm View →
Nov 13, 2025 8-K ftlf20251113_8k.htm View →
Nov 13, 2025 10-Q ftlf20250930_10q.htm View →
Sep 8, 2025 4 xslF345X05/form4-09082025_020907.xml View →
Aug 19, 2025 8-K ftlf20250819_8k.htm View →

Frequently Asked Questions about FTLF

What is the AI rating for FTLF?

FITLIFE BRANDS, INC. (FTLF) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.

What are FTLF's key strengths?

Claude: Strong revenue growth of 22.3% YoY with net income growth of 69.6% indicating operational leverage. Healthy profitability metrics with 40.5% gross margin and 14.0% operating margin in medicinal/botanical sector.

What are the risks of investing in FTLF?

Claude: Elevated leverage with 1.11x Debt/Equity ratio and $46.5M long-term debt against $41.9M equity. Tight liquidity position with 1.13x current ratio and low cash balance of $3.5M relative to $68.1M liabilities.

What is FTLF's revenue and growth?

FITLIFE BRANDS, INC. reported revenue of $55.5M.

Does FTLF pay dividends?

FITLIFE BRANDS, INC. does not currently pay dividends.

Where can I find FTLF SEC filings?

Official SEC filings for FITLIFE BRANDS, INC. (CIK: 0001374328) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is FTLF's EPS?

FITLIFE BRANDS, INC. has a diluted EPS of $0.47.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is FTLF a good stock to buy right now?

Based on our AI fundamental analysis in March 2026, FITLIFE BRANDS, INC. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is FTLF stock overvalued or undervalued?

Valuation metrics for FTLF: ROE of 11.2% (sector avg: 15%), net margin of 8.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy FTLF stock in 2026?

Our dual AI analysis gives FITLIFE BRANDS, INC. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is FTLF's free cash flow?

FITLIFE BRANDS, INC.'s operating cash flow is $7.2M, with capital expenditures of $37.0K. FCF margin is 12.9%.

How does FTLF compare to other Default stocks?

Vs Default sector averages: Net margin 8.4% (avg: 12%), ROE 11.2% (avg: 15%), current ratio 1.13 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 25, 2026 | Data as of: 2025-09-30 | Powered by Claude AI